A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

NCT04875754 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Knee

Interventions

GENETIC: ICM-203
DRUG: Placebo

Sponsor

ICM Biotech Australia Pty Ltd.